4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

4D Molecular Therapeutics (4DMT) announced positive 2-year results from its PRISM Phase 2b clinical trial of 4D-150, an intravitreal gene therapy for wet age-related macular degeneration (AMD). The single-dose treatment demonstrated consistent maintenance of visual acuity and anatomic control with 78-87% reduction in treatment burden compared to standard aflibercept injections. The therapy was well-tolerated with no new safety concerns or intraocular inflammation cases beyond the first 6 months.